An Evaluation of the Utility of the Breast Reconstruction Risk Assessment Score Risk Model in Prepectoral Tissue Expander Breast Reconstruction

2020 ◽  
Vol 84 ◽  
pp. S318-S322 ◽  
Author(s):  
Shanique Martin ◽  
Elizabeth Turner ◽  
Alan Nguyen ◽  
Brian Thornton ◽  
Rahim S. Nazerali
2006 ◽  
Vol 54 (S 1) ◽  
Author(s):  
T Krabatsch ◽  
M Bechtel ◽  
C Detter ◽  
T Fischlein ◽  
FC Riess ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e044219
Author(s):  
J X Harmeling ◽  
Kevin Peter Cinca ◽  
Eleni-Rosalina Andrinopoulou ◽  
Eveline M L Corten ◽  
M A Mureau

IntroductionTwo-stage implant-based breast reconstruction is the most commonly performed postmastectomy reconstructive technique. During the first stage, a tissue expander creates a sufficiently large pocket for the definite breast implant placed in the second stage. Capsular contracture is a common long-term complication associated with implant-based breast reconstruction, causing functional complaints and often requiring reoperation. The exact aetiology is still unknown, but a relationship between the outer surface of the implant and the probability of developing capsular contracture has been suggested. The purpose of this study is to determine whether polyurethane-covered implants result in a different capsular contracture rate than textured implants.Methods and analysisThe Textured Implants versus Polyurethane-covered Implants (TIPI) trial is a multicentre randomised controlled trial with a 1:1 allocation rate and a follow-up of 10 years. A total of 321 breasts of female adults undergoing a two-stage breast reconstruction will be enrolled. The primary outcome is capsular contracture at 10-year follow-up which is graded with the modified Baker classification. It is analysed with survival analysis using a frailty model for clustered interval-censored data, with both an intention-to-treat and per-protocol approach. Secondary outcomes are other complication rates, surgical revision rate, patient satisfaction and quality of life and user-friendliness. Outcomes are measured 2 weeks, 6 months, 1, 2, 3, 5 and 10 years postoperatively. Interim analysis is performed when 1-year, 3-year and 5-year follow-up is completed.Ethics and disseminationThe trial has been reviewed and approved by the Medical Research Ethics Committee of the Erasmus MC, University Medical Centre Rotterdam (MEC-2018-126) and locally by each participating centre. Written informed consent will be obtained from each study participant. The results will be disseminated by publication in peer-reviewed journals.Trial registrationNTR7265.


2013 ◽  
Vol 70 (4) ◽  
pp. 447-453 ◽  
Author(s):  
Richard S. Gaster ◽  
Aaron J. Berger ◽  
Stefanie D. Monica ◽  
Robert T. Sweeney ◽  
Ryan Endress ◽  
...  

2013 ◽  
Vol 17 (2) ◽  
pp. 132-141
Author(s):  
Evangelos Hytopoulos ◽  
Martin L. Lee ◽  
Michael Beggs ◽  
Cynthia French ◽  
Kuo Bianchini Tong

2021 ◽  
Vol 331 ◽  
pp. e160-e161
Author(s):  
S. Asil ◽  
E. Murat ◽  
V.Ö. Barış ◽  
H. Taşkan ◽  
U.Ç. Yüksel

Sign in / Sign up

Export Citation Format

Share Document